Roche wins FDA approval for Gazyva in pMN after 36.1% remission rate
AI Summary- Roche received FDA approval for Gazyva/Gazyvaro to treat adults with progressing primary membranous nephropathy.
- Gazyva/Gazyvaro achieved 36.1% complete proteinuria remission at 104 weeks versus 5.7% for tacrolimus.
- MAJESTY enrolled 142 adults, with results presented at ERA and published in the New England Journal of Medicine.